A remarkable study was recently published by Rojas and colleagues in the journal Nature. In their study, sixteen people underwent surgery for pancreatic cancer. The removed cancer was then analyzed, and a personal mRNA vaccine was developed to target 20 unique features (neoantigens) of each of the sixteen cancers. Each participant was then vaccinated with their personal vaccine, and received chemotherapy and an immune check point inhibitor. The results were remarkable. The authors showed that some patients developed an immune reaction (a T cell response) to the unique features present on their cancers. Although half of the patients did not respond, those that did had no evidence of disease 18 months after surgery.

The generation of personalized therapies can be extremely expensive, and this approach has a long way to go (Phase 2 and phase 3 trials are needed), this study “established the feasibility of using mRNA-based neoantigen vaccines for pancreatic cancer.”